Kenji Ota, MD, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Appointments
Immunobiology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Nagasaki University, Biomedical Science (2021)
- MD
- Kyushu University (2012)
Research
Copy Link
Overview
Public Health Interests
Biomarkers; Emerging Infectious Diseases; Immunology; Infectious Diseases; Respiratory Disease/Infections; Microbiome; COVID-19
ORCID
0000-0001-7180-0820- View Lab Website
Iwasaki
Research at a Glance
Publications Timeline
A big-picture view of Kenji Ota's research output by year.
31Publications
271Citations
Publications
Featured Publications
Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination
Ota K, Sakai H, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Izumikawa K, Mukae H, Tun M, Morita K, Yanagihara K. Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination. Virus Research 2023, 339: 199294. PMID: 38056502, PMCID: PMC10749273, DOI: 10.1016/j.virusres.2023.199294.Peer-Reviewed Original ResearchCitationsAltmetricThe evaluation of a rapid microfluidic immunofluorescence antigen test in detecting the infectiousness of COVID-19 patients
Ota K, Kodama H, Kawamoto Y, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Izumikawa K, Mukae H, Tun M, Morita K, Yanagihara K. The evaluation of a rapid microfluidic immunofluorescence antigen test in detecting the infectiousness of COVID-19 patients. BMC Infectious Diseases 2023, 23: 823. PMID: 37996783, PMCID: PMC10668452, DOI: 10.1186/s12879-023-08821-9.Peer-Reviewed Original ResearchCitationsAltmetricSerological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
Ota K, Murakami S, Ishihara K, Sasaki D, Usui T, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Furumoto A, Asoh N, Yoshimine H, Sawai T, Onizuka M, Makimoto N, Izumikawa K, Mukae H, Kohno S, Yanagihara K. Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history. Vaccine X 2023, 13: 100282. PMID: 36960104, PMCID: PMC10022459, DOI: 10.1016/j.jvacx.2023.100282.Peer-Reviewed Original ResearchAltmetricPerformance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens
Ota K, Kurahara R, Tsukamoto C, Kawamoto Y, Akamatsu N, Sasaki D, Mitsumoto-Kaseida F, Sakamoto K, Kosai K, Hasegawa H, Yamamoto K, Izumikawa K, Mukae H, Yanagihara K. Performance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens. Microbiology Spectrum 2023, 11: e03259-22. PMID: 36779750, PMCID: PMC10101093, DOI: 10.1128/spectrum.03259-22.Commentaries, Editorials and LettersCitationsDetection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples
Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, Kosai K, Miyazaki T, Hasegawa H, Fujita A, Tashiro M, Tanaka T, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S. Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples. PLOS ONE 2021, 16: e0252964. PMID: 34111203, PMCID: PMC8191987, DOI: 10.1371/journal.pone.0252964.Peer-Reviewed Original ResearchCitationsAltmetricEfficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia
Ota K, Kaku N, Yanagihara K. Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia. Journal Of Infection And Chemotherapy 2020, 26: 1237-1243. PMID: 32868198, DOI: 10.1016/j.jiac.2020.07.002.Peer-Reviewed Original ResearchCitations
2026
Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study)
Yamamoto K, Iwanaga N, Umemura A, Sawai T, Sumiyoshi M, Hashiguchi K, Mori Y, Ishii H, Futsuki Y, Kiyohara M, Ota K, Kosai K, Sasaki D, Takamatsu Y, Inoue S, Morita K, Tsutsui S, Ashizawa K, Takazono T, Sakamoto N, Hosogaya N, Tashiro M, Tanaka T, Izumikawa K, Yanagihara K, Mukae H. Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). Therapeutic Advances In Infectious Disease 2026, 13: 20499361261431488. PMID: 41884792, PMCID: PMC13009641, DOI: 10.1177/20499361261431488.Peer-Reviewed Original ResearchAltmetricRapid Typing of Extended‐Spectrum β‐Lactamase (ESBL)‐ and Metallo‐β‐Lactamase (MBL)‐Producing Enterobacterales Using Fourier Transform Infrared (FT‐IR) Spectroscopy
Kawamoto Y, Kosai K, Murata M, Ota K, Mitsumoto‐Kaseida F, Kaku N, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. Rapid Typing of Extended‐Spectrum β‐Lactamase (ESBL)‐ and Metallo‐β‐Lactamase (MBL)‐Producing Enterobacterales Using Fourier Transform Infrared (FT‐IR) Spectroscopy. MicrobiologyOpen 2026, 15: e70218. PMID: 41627971, PMCID: PMC12863417, DOI: 10.1002/mbo3.70218.Peer-Reviewed Original Research
2025
Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation
Ota K, Kaku N, Mitsumoto-Kaseida F, Uno N, Kosai K, Takazono T, Hasegawa H, Sakamoto K, Morinaga Y, Izumikawa K, Mukae H, Mikamo H, Yanagihara K. Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation. Microbiology Spectrum 2025, 14: e02568-25. PMID: 41433406, PMCID: PMC12889036, DOI: 10.1128/spectrum.02568-25.Peer-Reviewed Original ResearchThis study investigates the effectiveness of cefiderocol against ventilator-associated pneumonia in mice, showing pathogen-specific dose adjustments are needed for optimal treatment of resistant bacteria.Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study)
Yamamoto K, Inoue T, Ikeda T, Sawai T, Nagayoshi Y, Hashiguchi K, Futsuki Y, Matsubara Y, Harada Y, Ashizawa N, Fukahori S, Iwanaga N, Takazono T, Kido T, Ishimoto H, Hosogaya N, Sakamoto N, Tashiro M, Tanaka T, Fukushima C, Jounai K, Tsuji R, Fujiwara D, Ota K, Kosai K, Furumoto A, Yanagihara K, Izumikawa K, Mukae H. Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study). Infectious Diseases And Therapy 2025, 14: 2835-2851. PMID: 41138036, PMCID: PMC12602773, DOI: 10.1007/s40121-025-01246-8.Peer-Reviewed Original ResearchCitationsAltmetric
Get In Touch
Copy Link
Contacts
Email
Academic Office Number